MarketPR
TECHCiena Backlog Hits $8.5B as Cloud Orders Drive 29% Revenue GrowthOct 22DEALSZacks ranks TotalEnergies, American Integrity, Quaker Houghton top momentum picksOct 22PRODUCTTrailer for 'Best Pancakes in the County' shows Nicolas Cage's altered appearanceOct 22MARKETSFort Technology leads most active stocks with 166 million shares tradedOct 22ENERGYUnconfirmed Qatar-Pakistan Iran peace proposal lifts stocks, weighs on oilOct 22ENERGYEnergy stocks dip as Houthi strikes hit Saudi infrastructureOct 22REGULATORYSEGG Media Requests Nasdaq Stay to Avoid October 23 Trading SuspensionOct 22WORLDFox News poll finds Black voters more supportive of Israel than other groupsOct 22MACROLockheed Martin Integrates Satellites and Interceptors for Layered DefenseOct 22REGULATORYHealthcare Triangle to Execute 1-for-20 Reverse Split for Nasdaq ComplianceOct 22TECHCiena Backlog Hits $8.5B as Cloud Orders Drive 29% Revenue GrowthOct 22DEALSZacks ranks TotalEnergies, American Integrity, Quaker Houghton top momentum picksOct 22PRODUCTTrailer for 'Best Pancakes in the County' shows Nicolas Cage's altered appearanceOct 22MARKETSFort Technology leads most active stocks with 166 million shares tradedOct 22ENERGYUnconfirmed Qatar-Pakistan Iran peace proposal lifts stocks, weighs on oilOct 22ENERGYEnergy stocks dip as Houthi strikes hit Saudi infrastructureOct 22REGULATORYSEGG Media Requests Nasdaq Stay to Avoid October 23 Trading SuspensionOct 22WORLDFox News poll finds Black voters more supportive of Israel than other groupsOct 22MACROLockheed Martin Integrates Satellites and Interceptors for Layered DefenseOct 22REGULATORYHealthcare Triangle to Execute 1-for-20 Reverse Split for Nasdaq ComplianceOct 22
NewsMacro

Virax Biolabs (VRAX): $3.3 million gross proceeds from preferred investment option exercise

The number moving the tape for Virax Biolabs Group Limited (Nasdaq: VRAX) is $3.3 million, the gross proceeds from a definitive agreement the London-based company entered July 9, 2026. The deal covers the immediate exercise of certain outstanding preferred investment options. The next confirmable milestone is the formal filing from Virax Biolabs detailing the full transaction terms.

By Renata OstrowskiMacro DeskJuly 18, 20262 min read
Share

Key takeaways

  • Virax Biolabs Group Limited (Nasdaq: VRAX), a London-based company, entered a definitive agreement on July 9, 2026 for the immediate exercise of certain outstanding preferred investment options.
  • The agreement will generate gross proceeds of $3.3 million to the company upon completion.
  • The preferred investment options were already outstanding before the July 9 announcement, meaning they predated this agreement.
  • The complete transaction terms, including the aggregate amount covered by the options, are to be provided in the company's formal disclosures.
  • The next confirmable milestone is Virax Biolabs' formal filing detailing the full transaction terms and the aggregate covered under the exercised options.

The number moving the tape for Virax Biolabs Group Limited (Nasdaq: VRAX) is $3.3 million, the gross proceeds from a definitive agreement the London-based company entered July 9, 2026. The deal covers the immediate exercise of certain outstanding preferred investment options. The next confirmable milestone is the formal filing from Virax Biolabs detailing the full transaction terms.

The transaction

The preferred investment options were outstanding before the July 9 announcement, meaning the instruments predated this agreement. Virax Biolabs entered the definitive agreement for their immediate exercise. Gross proceeds of $3.3 million flow to the company on completion. The announcement noted the options cover the purchase of up to an aggregate amount, with complete terms to follow in the company's formal disclosures.

What to watch

VRAX trades on the Nasdaq. The definitive agreement is already in hand. What the setup turns on now is the complete filing from Virax Biolabs confirming the aggregate covered under the exercised options and the full terms behind the $3.3 million gross proceeds figure.

Related reading

About this story

Filed by the macro desk of MarketPR on July 18, 2026. Source: prnewswire.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Fort Technology leads most active stocks with 166 million shares traded

Fort Technology Inc. led trading volume among the most active stocks listed on the Nasdaq composite, New York Stock Exchange and NYSE American, exchanging 166,480,803 shares. The Associated Press reported these figures for the most active…

Miles Broadbent2 min read
02Macro · TSLA

Tesla Q3 2026 cash flow beats expectations despite revenue miss

Tesla (TSLA) reported third-quarter 2026 results that missed on revenue but significantly exceeded expectations for profitability and cash generation. The company generated positive free cash flow of $1.53 billion, a sharp contrast to the…

Grant Halloran2 min read
03Macro

Elbit Systems Q2 Aerospace Sales Fall 7.8% Despite Overall Revenue Growth

Elbit Systems Ltd. (NASDAQ: ESLT) reported second-quarter revenue growth of 15.9% year over year, yet its aerospace segment recorded a 7.8% decline in sales to $495 million. The stock is up more than 20% in 2026, outperforming the S&P 500…

Grant Halloran2 min read

Frequently asked

How much money will Virax Biolabs raise from this deal?

The agreement will generate $3.3 million in gross proceeds to the company upon completion.

When did Virax Biolabs enter the agreement?

Virax Biolabs entered the definitive agreement on July 9, 2026.

What exactly does the agreement cover?

It covers the immediate exercise of certain outstanding preferred investment options that were already in place before the July 9 announcement.

Where does Virax Biolabs stock trade?

Virax Biolabs trades on the Nasdaq under the ticker VRAX.

What details are still unknown about the transaction?

The complete terms, including the aggregate amount covered under the exercised options, are still to be confirmed in the company's formal filing.